Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Jose Perez Lopez

Orthopaedic Surgery Mayaguez, PR Medical Doctor

NPI 1588016182 CMS profile 9097466

877 Ave Hostos, Mayaguez, PR 00680

Open in the dashboard

General payments

$11,960

31 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jose Perez Lopez of Mayaguez, PR is reported in the CMS Open Payments database as having received $11,960 across 31 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,395 6
2024 General $454 5
2023 General $1,744 13
2022 General $337 3
2021 General $6,975 3
2020 General $55 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Perez Lopez
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jose Perez Lopez were reported at $2,395. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jose Perez Lopez Orthopaedic Surgery median Middle half National median
2019 $0 $644 $140–$2,844 $163
2020 $55 $312 $75–$1,860 $114
2021 $6,975 $520 $117–$2,495 $132
2022 $337 $598 $128–$2,731 $149
2023 $1,744 $461 $128–$2,264 $160
2024 $454 $497 $134–$2,475 $164
2025 $2,395 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. NuVasive, Inc. $6,916 3 payments
  2. Zavation LLC $2,539 7 payments
  3. Medtronic, Inc. $1,637 10 payments
  4. Cerapedics, Inc. $279 3 payments
  5. Augmedics Inc. $190 2 payments
  6. Carlsmed, Inc. $163 1 payment
  7. Aesculap Implant Systems, LLC $147 1 payment
  8. Merck Sharp & Dohme Corporation $46 2 payments
  9. Genzyme Corporation $31 1 payment
  10. Acumed LLC $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Grant $6,800 1 payment
  2. Travel and Lodging $3,689 11 payments
  3. Food and Beverage $1,471 19 payments
Products named General payments · program years 2020–2025
  1. CD HORIZON SPINAL SYSTEM $1,070 6 payments
  2. Xvision $952 10 payments
  3. GRAFTONAND GRAFTON PLUSDEMINERALIZED BONE MATRIX (DBM) $567 4 payments
  4. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $279 3 payments
  5. aprevo $163 1 payment
  6. ACTIVL $147 1 payment
  7. XLIF $61 1 payment
  8. RELINE Spine/Spine Surgery $61 1 payment
  9. Simplify Cervical Artificial Disc $61 1 payment
  10. RELINE Spine/Spine Surgery $55 1 payment
  11. Other $101 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

822

Median for Orthopedic Surgery: 203

Drug cost

$8,108

Median for Orthopedic Surgery: $1,433

Branded share of claims

49%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Acetaminophen-Codeine Acetaminophen With Codeine Brand 203 $3,759
Cefadroxil Generic 196 $1,652
Tramadol Hcl-Acetaminophen Tramadol Hcl/Acetaminophen Brand 181 $778
Celecoxib Generic 47 $690
Methylprednisolone Generic 58 $470
Ciprofloxacin Hcl Generic 30 $184
Cyclobenzaprine Hcl Generic 41 $177
Gabapentin Generic 16 $136
Pregabalin Generic 11 $94
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $86

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$12,223

Medicare's payments for the services billed

Medicare patients

14

Average age 75

Services billed

47

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record